ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Effects of the Addition of Mycophenolate Mofetil on Renal Outcomes in Liver Transplant Recipients: A Single Center Review

M. Henry, M. Vacha.

Nebraska Medicine, Omaha, NE.

Meeting: 2018 American Transplant Congress

Abstract number: C207

Keywords: Glomerular filtration rate (GFR), IMPDH Inhibitor, Liver transplantation, Renal dysfunction

Session Information

Date: Monday, June 4, 2018

Session Name: Poster Session C: Liver: Immunosuppression and Rejection

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Related Abstracts
  • Evaluation of Renal Function After a Transition to Everolimus or Mycophenolate Mofetil in Liver Transplant Recipients.
  • One Year Outcomes of Low-Dose vs Very Low-Dose Extended-Release Tacrolimus/Mycophenolate mofetil in De Novo Kidney Transplantation: A Multi-Center Randomized Controlled Trial.

Purpose: To evaluate the use of mycophenolate mofetil (MMF) and its effects on renal outcomes in liver transplant recipients

Methods: Adult liver transplant recipients from September 1, 2012 to September 30, 2015 at a single center were identified retrospectively and categorized based upon the immunosuppression regimen received. Patients were separated into two groups based upon whether or not they received at least one dose of MMF in addition to a calcineurin inhibitor and corticosteroid during their first year post-transplant (MMF group and no-MMF group). Patients were excluded from analysis if they were less than 19 years of age, received induction with antithymocyte globulin, or deceased within 6 months post-transplant. The primary outcome was change in renal function at 6 months from baseline. Secondary outcomes included change in renal function at 12 months, biopsy-proven rejection, infectious complications, leukopenia, and thrombocytopenia. Descriptive statistics were used for demographic data. Chi-square and Fisher's exact test were used for categorical variables and Wilcoxon rank sum test for continuous variables.

Results: Of 255 adult liver transplant recipients, 146 patients were included in the analysis. Of the 146 patients, twelve did not receive MMF during the first year post-transplant. Average change in glomerular filtration rate (GFR) (mL/min/1.73m2) at 6 months was -21.4 in the no-MMF group vs. -12 in the MMF group (p=0.15). Average change in GFR (mL/min/1.73m2) at 12 months was -21.2 in control group vs. -11.1 in MMF group (p=0.20). Increased incidence of all secondary outcomes were observed in the MMF group. However, study groups were not balanced with substantially more patients in the MMF group. Patients in the MMF group appeared to have a trend toward less renal dysfunction. The majority of patients who received at least one dose of MMF had stopped MMF by 6 months post-transplant. Those who remained on MMF appeared to have sustained renal dysfunction, suggesting MMF was being used to prevent further renal injury.

Conclusions: These findings suggest that the addition of MMF to a calcineurin inhibitor and coriticosteroid within one-year post-transplant may lead to less renal dysfunction in liver transplant recipients. It is unknown whether sustaining MMF for the full year provides additional benefit. Study of optimal duration and timing of MMF should continue to be evaluated.

CITATION INFORMATION: Henry M., Vacha M. Effects of the Addition of Mycophenolate Mofetil on Renal Outcomes in Liver Transplant Recipients: A Single Center Review Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Henry M, Vacha M. Effects of the Addition of Mycophenolate Mofetil on Renal Outcomes in Liver Transplant Recipients: A Single Center Review [abstract]. https://atcmeetingabstracts.com/abstract/effects-of-the-addition-of-mycophenolate-mofetil-on-renal-outcomes-in-liver-transplant-recipients-a-single-center-review/. Accessed March 8, 2021.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Search
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Home
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.